
    
      Approximately 36 participants will be enrolled sequentially into 3 cohorts. Within each
      cohort of 12 participants, 9 will be randomized to PLN-74809 and 3 will be randomized to
      placebo (3:1 ratio).

        -  In Part 1, approximately 12 participants will be randomized to Dose level 1 of PLN-74809
           or placebo QD

        -  In Part 2, approximately 12 participants will be randomized to Dose level 2 of PLN-74809
           or placebo QD

        -  In Part 3, approximately 12 participants will be randomized to Dose level 3 of PLN-74809
           or placebo QD
    
  